FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-designated drug, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 (PD-L1), as determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sul, Joohee, Blumenthal, Gideon M., Jiang, Xiaoping, He, Kun, Keegan, Patricia, Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861368/
https://www.ncbi.nlm.nih.gov/pubmed/27026676
http://dx.doi.org/10.1634/theoncologist.2015-0498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861368/
https://www.ncbi.nlm.nih.gov/pubmed/27026676
http://dx.doi.org/10.1634/theoncologist.2015-0498

Ejemplares similares